068760 (Celltrion Pharm Inc) vs KOSPI 200 Comparison

068760

KOSPI 200

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

068760

KOSPI 200

Difference

1Y 3Y 5Y 10Y 15Y 20Y

068760

KOSPI 200

Add Stock

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

KOSPI 200

068760

LLY

DPH

NOVO B

JNJ

Add Stock

1Y 3Y 5Y 10Y 15Y 20Y

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Celltrion Pharm Inc
Glance View

Market Cap

2.5T KRW

Industry

Pharmaceuticals

In the bustling world of pharmaceuticals, Celltrion Pharm Inc. has carved a niche for itself, leveraging innovation and strategic market positioning. Born out of South Korea, this dynamic player operates with a vision to transform the pharmaceutical landscape, particularly through its expertise in biosimilars and small molecule drugs. By focusing on cutting-edge research and development, Celltrion Pharm is able to produce high-quality, cost-effective alternatives to branded biologics, which are essential for treating diseases such as cancer and autoimmune disorders. With a comprehensive pipeline of biosimilar products, the company effectively taps into a growing demand, driven by global healthcare systems seeking cost-efficient therapeutics amidst rising healthcare expenditures. Celltrion Pharm's operational strategy extends beyond product innovation. It encompasses robust manufacturing infrastructure and a global distribution network that underscores its financial growth. By owning state-of-the-art production facilities, the company ensures both the scale and quality required to meet international benchmarks, which is pivotal in the highly regulated pharmaceutical industry. Furthermore, strategic alliances and partnerships bolster its market reach, ensuring that its products have strong footholds not just locally, but globally. Through these multifaceted endeavors—ranging from R&D to distribution—the company has positioned itself as a formidable force, achieving sustainable revenue streams by addressing critical healthcare needs and optimizing drug accessibility worldwide.

View Celltrion Pharm Inc Analysis

Intrinsic Value

What is Intrinsic Value?

Economic Moat is a concept popularized by Warren Buffett to describe a company's durable competitive advantage. It represents the 'moat' that protects a company from competitors and helps it sustain profitability over the long term. Our analysis of the past 10 years showed that companies with a wide economic moat significantly outperformed the market, delivering +645% returns compared to +189% for the S&P 500.

Our research into Economic Moat performance spans the past 10 years and focuses on companies with a wide economic moat. For this analysis, we calculated the average stock price returns of these companies, comparing them to the performance of the S&P 500 index over the same period.

The results were compelling: wide moat stocks achieved a remarkable +645% average return, compared to +188% for the broader market. This difference highlights the long-term benefits of investing in businesses that can maintain their market position and pricing power over time.

Note: This research does not account for survivorship bias. Past performance is not indicative of future results.

Determining whether a company has an economic moat requires both a deep dive into financial metrics and a qualitative assessment of its competitive position. Our analysts conduct a rigorous evaluation that focuses on identifying structural advantages that enable a company to sustain profitability and defend its market share over the long term.

The process begins with an analysis of a company’s historical financial performance. We assess how consistently the company has generated returns above its cost of capital and whether those returns have been stable or improving. However, financial performance alone doesn’t reveal the full picture. To understand the sources of these advantages, we evaluate five key drivers of economic moats:

Network Effect: We analyze whether the value of a company’s product or service grows as its user base expands. Platforms like payment systems or marketplaces benefit from this self-reinforcing.

Switching Costs: We assess whether customers face significant costs or disruptions when switching to a competitor’s product or service. High switching costs create customer stickiness and provide pricing power.

Intangible Assets: Strong brands, patents, and regulatory licenses can protect a company’s market position by creating barriers for competitors or enabling premium pricing. For example, a well-recognized consumer brand may command higher customer loyalty and margins.

Efficient scale: Occurs when a market is optimally served by one or a few players, making it unprofitable for new entrants to compete. This typically happens in industries with high fixed costs or geographic constraints, such as utilities or pipelines.

Cost Advantage: Companies with structural cost advantages can produce goods or services at a lower cost than their competitors, enabling them to offer competitive pricing or maintain higher margins. These advantages often arise from economies of scale, superior supply chain management, or proprietary technology. Firms like Walmart leverage their massive scale to negotiate better terms with suppliers, allowing them to undercut competitors on price.

By examining these factors in combination with a company’s financial performance and market positioning, we classify each company into one of three categories:

This rigorous evaluation ensures that our moat ratings are both comprehensive and reliable, giving investors the tools they need to make well-informed, long-term decisions.

JP	N	Nichi-Iko Pharmaceutical Co Ltd TSE:4541	Add
US		Eli Lilly and Co NYSE:LLY	Add
UK		Dechra Pharmaceuticals PLC LSE:DPH	Add
DK		Novo Nordisk A/S CSE:NOVO B	Add
US		Johnson & Johnson NYSE:JNJ	Add
US		Merck & Co Inc NYSE:MRK	Add
CH		Roche Holding AG SIX:ROG	Add
UK		AstraZeneca PLC LSE:AZN	Add
CH		Novartis AG SIX:NOVN	Add
US		Pfizer Inc NYSE:PFE	Add

JP	N	Nichi-Iko Pharmaceutical Co Ltd TSE:4541	Select
US		Eli Lilly and Co NYSE:LLY	Select
UK		Dechra Pharmaceuticals PLC LSE:DPH	Select
DK		Novo Nordisk A/S CSE:NOVO B	Select
US		Johnson & Johnson NYSE:JNJ	Select
US		Merck & Co Inc NYSE:MRK	Select
CH		Roche Holding AG SIX:ROG	Select
UK		AstraZeneca PLC LSE:AZN	Select
CH		Novartis AG SIX:NOVN	Select
US		Pfizer Inc NYSE:PFE	Select

JP	N	Nichi-Iko Pharmaceutical Co Ltd TSE:4541	Add
US		Eli Lilly and Co NYSE:LLY	Add
UK		Dechra Pharmaceuticals PLC LSE:DPH	Add
DK		Novo Nordisk A/S CSE:NOVO B	Add
US		Johnson & Johnson NYSE:JNJ	Add
US		Merck & Co Inc NYSE:MRK	Add
CH		Roche Holding AG SIX:ROG	Add
UK		AstraZeneca PLC LSE:AZN	Add
CH		Novartis AG SIX:NOVN	Add
US		Pfizer Inc NYSE:PFE	Add

HR	C	CROBEX INDX:CRBEX	Add
SA	T	Tadawul All Share INDX:TASI	Add
TH	S	SET Index INDX:SET	Add
ID	J	Jakarta Composite Index INDX:JKSE	Add
GR	A	Athens General Composite INDX:ATG	Add
BR	B	BOVESPA INDX:BVSP	Add
AR	S	S&P Merval INDX:MERV	Add
MX	M	Mexico S&P/BMV IPC INDX:MXX	Add
CZ	P	PX Prague Stock Index INDX:PX	Add
RU	M	MOEX Russia INDX:IMOEX	Add

	Franklin Covey Co NYSE:FC	31.07 USD -11.98%
	Mohawk Industries Inc NYSE:MHK	118.46 USD 0.15%
	Ardmore Shipping Corp NYSE:ASC	13.35 USD 6.29%
	ASGN Inc NYSE:ASGN	85.29 USD -1.88%
	Skyworks Solutions Inc NASDAQ:SWKS	91.3368 USD -1.4%
	Weatherford International PLC NASDAQ:WFRD	71.09 USD -1.44%

068760

vs

KOSPI 200

Stocks Performance
068760 vs KOSPI 200

Performance Gap
068760 vs KOSPI 200

Performance By Year
068760 vs KOSPI 200

Competitors Performance
Celltrion Pharm Inc vs Peers

Celltrion Pharm Inc
Glance View

Company

Help

Tools

Stocks

	Johnson & Johnson NYSE:JNJ	142.52 USD 0.18%
	Bank of America Corp NYSE:BAC	45.075 USD -2.46%
	Mastercard Inc NYSE:MA	505.22 USD -2.16%
	Salesforce Inc NYSE:CRM	320.31 USD -2.02%
	Abbvie Inc NYSE:ABBV	176.05 USD -1.37%
	Home Depot Inc NYSE:HD	389.66 USD 0.64%

	Arista Networks Inc NYSE:ANET	114.74 USD -0.67%
	Visa Inc NYSE:V	307.325 USD -1.69%
	Texas Pacific Land Corp NYSE:TPL	1 296.175 USD 1.59%
	KLA Corp NASDAQ:KLAC	680.53 USD -0.83%
	Manhattan Associates Inc NASDAQ:MANH	266.375 USD -2.24%
	Pinduoduo Inc NASDAQ:PDD	95.3253 USD -4.98%

	Salesforce Inc NYSE:CRM	320.31 USD -2.02%
	ServiceNow Inc NYSE:NOW	1 033.3 USD -1.5%
	EOG Resources Inc NYSE:EOG	130.82 USD 1.84%
	Copart Inc NASDAQ:CPRT	55.859 USD -1.62%
	Applied Materials Inc NASDAQ:AMAT	171.18 USD -3.28%
	Synopsys Inc NASDAQ:SNPS	489.43 USD -2.5%

	Johnson & Johnson NYSE:JNJ	142.52 USD 0.18%
	Berkshire Hathaway Inc NYSE:BRK.A	664 714.01 USD -1.95%
	Bank of America Corp NYSE:BAC	45.075 USD -2.46%
	Mastercard Inc NYSE:MA	505.22 USD -2.16%
	UnitedHealth Group Inc NYSE:UNH	523.71 USD -0.15%
	Exxon Mobil Corp NYSE:XOM	106.575 USD -0.33%

068760 vs KOSPI 200

Stocks Performance 068760 vs KOSPI 200

Performance Gap 068760 vs KOSPI 200

Performance By Year 068760 vs KOSPI 200

Competitors Performance Celltrion Pharm Inc vs Peers

Celltrion Pharm Inc Glance View

Company

Help

Tools

Stocks

068760

vs

KOSPI 200

Stocks Performance
068760 vs KOSPI 200

Performance Gap
068760 vs KOSPI 200

Performance By Year
068760 vs KOSPI 200

Competitors Performance
Celltrion Pharm Inc vs Peers

Celltrion Pharm Inc
Glance View